physioneal 40 glucose 1,36% w/v/13,6 mg/ml clear-f peritonealdialysevæske
baxter a/s - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natrium(s)-lactat opløsning, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske - 13,6 mg/ml
physioneal 40 glucose 2,27% w/v/22,7 mg/ml clear-f peritonealdialysevæske
baxter a/s - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natrium(s)-lactat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske - 22,7 mg/ml
physioneal 40 glucose 3,86% w/v/38,6 mg/ml clear-f peritonealdialysevæske
baxter a/s - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natrium(s)-lactat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske - 38,6 mg/ml
tetraspan 100 mg/ml infusionsvæske, opløsning
b. braun melsungen - Æblesyre, calciumchloriddihydrat, hydroxyethylstivelse, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 100 mg/ml
nutrineal pd4 peritonealdialysevæske
baxter a/s - alanin, arginin, calciumchloriddihydrat, glycin, histidin, isoleucin, leucin, lysinhydrochlorid, magnesiumchloridhexahydrat, methionin, natriumchlorid, natriumlactat, phenylalanin, prolin, serin, threonin, tryptophan, tyrosin, valin - peritonealdialysevæske
kodamid "dak" 250+9,6+50+150+80 mg tabletter
orifarm healthcare a/s - caffein, codeinphosphathemihydrat, magnesiumhydroxid, tungt, propyphenazon, salicylamid - tabletter - 250+9,6+50+150+80 mg
kodimagnyl ikke-stoppende "dak" 500+9,6 mg filmovertrukne tabletter
orifarm healthcare a/s - acetylsalicylsyre, codeinphosphathemihydrat, magnesiumhydroxid, tungt - filmovertrukne tabletter - 500+9,6 mg
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
sprycel
bristol-myers squibb pharma eeig - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - sprycel er indiceret til behandling af pædiatriske patienter med nyligt diagnosticeret philadelphia-kromosom-positiv kronisk myeloid leukæmi i kronisk fase (ph+ cml cp) eller ph+ cml cp resistente eller intolerant over for tidligere behandling, herunder imatinib. nydiagnosticerede ph+ akut lymfoblastær leukæmi (all) i kombination med kemoterapi. sprycel er indiceret til behandling af voksne patienter med nyligt diagnosticeret philadelphia-kromosom-positiv (ph+) kronisk myeloid leukæmi (cml) i den kroniske fase;kronisk, accelereret eller blast-cml-fase med resistens eller intolerans til forudgående behandling, herunder imatinib mesilate;ph+ akut lymfoblastær leukæmi (all) og lymfoid blast-cml med modstand eller intolerance over for tidligere behandling. sprycel er indiceret til behandling af pædiatriske patienter med nyligt diagnosticeret ph+ cml i kronisk fase (ph+ cml-cp) eller ph+ cml-cp resistente eller intolerant over for tidligere behandling, herunder imatinib.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.